Tazemetostat is the world’s first orally administered, selective EZH2 (enhancer of zeste homolog 2) inhibitor approved for marketing, and it belongs to epigenetic targeted therapeutic agents.
Аутентичный
Гарантия
Быстро возим
АнонимноАвторское право 2024@ BigBear Все права защищены Bigbear | Bigbear ФАРМАЦЕВТИКА